Abstract
The statins are the most important group of drugs for lipid-lowering therapy in the prevention of coronary heart disease. Greater reductions in LDL-cholesterol appear to be associated with greater benefits but the clinical efficacy and safety of statin treatment varies considerably from person to person because of a combination of phenotypic and genotypic factors. Pharmacogenetic studies have investigated the relationship between common genetic variants and the lipid responses to statin therapy and adverse events, and some candidate genes related to the pharmacodynamics and pharmacokinetics of different statins have been identified. Some of these genetic variants show a different frequency in different ethnic groups. This field of pharmacogenetic research is receiving considerable attention and many new findings have been reported recently. Pharmacogenetic and pharmacogenomic studies of statin therapy are likely to provide a better understanding of the effects of these drugs and to help with prediction of the most appropriate drug and dosage for each individual and whether the addition or substitution of other lipid modifying drugs may be necessary to achieve the most safe and effective prevention of coronary heart disease.
Keywords: Coronary heart disease, ethnic differences, HMG-CoA reductase inhibitors, LDL-cholesterol, pharmacogenetics
Current Pharmacogenomics and Personalized Medicine
Title: Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease
Volume: 7 Issue: 1
Author(s): M. Hu, V. W.L. Mak, T. T.W. Chu, M. M.Y. Waye and B. Tomlinson
Affiliation:
Keywords: Coronary heart disease, ethnic differences, HMG-CoA reductase inhibitors, LDL-cholesterol, pharmacogenetics
Abstract: The statins are the most important group of drugs for lipid-lowering therapy in the prevention of coronary heart disease. Greater reductions in LDL-cholesterol appear to be associated with greater benefits but the clinical efficacy and safety of statin treatment varies considerably from person to person because of a combination of phenotypic and genotypic factors. Pharmacogenetic studies have investigated the relationship between common genetic variants and the lipid responses to statin therapy and adverse events, and some candidate genes related to the pharmacodynamics and pharmacokinetics of different statins have been identified. Some of these genetic variants show a different frequency in different ethnic groups. This field of pharmacogenetic research is receiving considerable attention and many new findings have been reported recently. Pharmacogenetic and pharmacogenomic studies of statin therapy are likely to provide a better understanding of the effects of these drugs and to help with prediction of the most appropriate drug and dosage for each individual and whether the addition or substitution of other lipid modifying drugs may be necessary to achieve the most safe and effective prevention of coronary heart disease.
Export Options
About this article
Cite this article as:
Hu M., Mak W.L. V., Chu T.W. T., Waye M.Y. M. and Tomlinson B., Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease, Current Pharmacogenomics and Personalized Medicine 2009; 7 (1) . https://dx.doi.org/10.2174/187569209787582349
DOI https://dx.doi.org/10.2174/187569209787582349 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Depression and its Relation with Uncontrolled Hypertension and Increased Cardiovascular Risk
Current Hypertension Reviews The Role of Endothelial Dysfunction in Aortic Aneurysms
Current Pharmaceutical Design Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets 25OH-Vitamin D3 Levels in Obesity and Metabolic Syndrome—Unaltered in Young and not Correlated to Carotid IMT in All Ages
Current Pharmaceutical Design Getting Patients to Target- Implementing the Guidelines
Current Vascular Pharmacology Relationship Between Cigarette Smoking and Other Coronary Risk Factors in Atherosclerosis: Risk of Cardiovascular Disease and Preventive Measures
Current Pharmaceutical Design Health Benefits of Ipecac and Cephaeline: their Potential in Health Promotion and Disease Prevention
Current Bioactive Compounds Statins and Inflammation in Cardiovascular Disease
Current Pharmaceutical Design Editorial [“Current Aging Science”: An Important Platform for Reporting Advances in Aging-related Research]
Current Aging Science Neutrophil F-actin Dynamics in Familial Mediterranean Fever: The Unequal Effect of Colchicine on Activated Neutrophils
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Probiotics and Oral Health
Current Pharmaceutical Design Biochemical Markers of Renal Function
Current Medicinal Chemistry Hypertension and Counter-Hypertension Mechanisms in Giraffes
Cardiovascular & Hematological Disorders-Drug Targets Cardiac Toxicities of Antiangiogenic Therapies
Current Angiogenesis (Discontinued) A Scientific Approach to Anti-Ageing Therapies: State of the Art
Current Pharmaceutical Design Cathelicidins: Peptides with Antimicrobial, Immunomodulatory, Anti- Inflammatory, Angiogenic, Anticancer and Procancer Activities
Current Protein & Peptide Science Drug Eluting Stents and Beyond
Current Pharmaceutical Design Network Building of Proteins in a Biochemical Pathway: A Computational Biology Related Model for Target Discovery and Drug-Design
Current Bioinformatics Editorial (Epigenetics: A Paradigm Shift in Understanding Alzheimer’s Disease)
Current Alzheimer Research Research Progress of the UPR Mechanism and its Effect on Improving Foreign Protein Expression
Protein & Peptide Letters